Prognostic value of DCE-MRI in breast cancer patients undergoing neoadjuvant chemotherapy: a comparison with traditional survival indicators

European Radiology

Volumn 25, Issue 4, 2015, Pages 1097-1106

  Pickles, Martin D ^a   Lowry, Martin ^a   Manton, David J ^b   Turnbull, Lindsay W ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

^b HULL AND EAST YORKSHIRE HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Breast cancer; DCE MRI; Magnetic resonance imaging; Prognosis; Survival

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; PROGESTERONE RECEPTOR; CONTRAST MEDIUM; GADOLINIUM PENTETATE;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CONTRAST ENHANCEMENT; DISEASE FREE SURVIVAL; DYNAMIC CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SHORT COURSE THERAPY; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR VOLUME; ADJUVANT THERAPY; AGE; BREAST; BREAST NEOPLASMS; COMPARATIVE STUDY; DIAGNOSTIC USE; FOLLOW UP; IMAGE ENHANCEMENT; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME;

ADULT; AGE FACTORS; BREAST; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; CONTRAST MEDIA; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GADOLINIUM DTPA; HUMANS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; NEOADJUVANT THERAPY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84925534665     PISSN: 09387994     EISSN: 14321084     Source Type: Journal    
DOI: 10.1007/s00330-014-3502-5     Document Type: Article

References (19)

1. Connolly RM, Stearns V (2013) Current approaches for neoadjuvant chemotherapy in breast cancer. Eur J Pharmacol 717:58–66
2. Kaufmann M, Hortobagyi GN, Goldhirsch A et al (2006) Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: An update. J Clin Oncol 24:1940–1949
3. van de Hage JH, van de Velde CCJH, Mieog SJSD (2007) Preoperative chemotherapy for women with operable breast cancer. Cochrane Database Syst Rev Issue 2. Art. No.:CD005002. DOI: 10.1002/14651858.CD005002.pub2.
4. American Cancer Society (2014) Breast cancer survival rates by stage. [Online]. Available at: http://www.cancer.org/cancer/%20breastcancer/detailedguide/breast-cancer-survival-by-stage [Accessed: 4 February 2014].
5. Padhani AR, Khan AA (2010) Duffusion-weighted (DW) and dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) for monitoring anticancer therapy. Target Oncol 5:39–52
6. Koo HR, Cho N, Song IC et al (2012) Correlation of perfusion parameters on dynamic contrast-enhanced MRI with prognostic factors and subtypes of breast cancer. J Magn Reson Imaging 36:145–151
7. Bone B, Szabo BK, Perbeck LG, Veress B, Aspelin P (2003) Can contrast-enhanced MR imaging predict survival in breast cancer? Acta Radiol 44:373–378
8. Partridge SC, Gibbs JE, Essermann LJ et al (2005) MRI measurements of breast tumour volume predict response to neoadjuvant chemotherapy and recurrence-free survival. Am J Roentgenol 184:1774–1781
9. Johansen R, Jensen LR, Rydland J et al (2009) Predicting survival and early clinical response to primary chemotherapy for patients with locally advanced breast cancer using DCE-MRI. J Magn Reson Imaging 29:1300–1307
10. Pickles MD, Manton DJ, Lowry M, Turnbull LW (2009) Prognostic value of pre-treatment DCE-MRI parameters in predicting disease free and overall survival for breast cancer patients undergoing neoadjuvant chemotherapy. Eur J Radiol 71:498–505
11. Heldahl MG, Bathen TF, Rydland J et al (2010) Prognostic value of pretreatment dynamic contrast-enhanced MR imaging in breast cancer patients receiving neoadjuvant chemotherapy: Overall survival prediction from combined time course and volume analysis. Acta Radiol 6:604–612
12. Li SP, Makris A, Beresford MJ et al (2011) Use of dynamic contrast-enhanced MR imaging to predict survival in patients with primary breast cancer undergoing neoadjuvant chemotherapy. Radiology 260:68–78
13. Tuncbilek N, Tokatli F, Altaner S et al (2012) Prognostic value DCE-MRI parameters in predicting factor disease free survival and overall survival for breast cancer patients. Eur J Radiol 81:863–867
14. Dietzel M, Zoubi R, Vag T et al (2013) Association between survival in patients with primary invasive breast cancer and computer aided MRI. J Magn Reson Imaging 37:146–155
15. Jones EF, Sinha SP, Newitt DC et al (2013) MRI enhancement in stromal tissue surrounding breast tumours: Association with recurrence free surivival following neoadjuvant chemotherapy. Plos One 8:1–8
16. Yi A, Cho N, Im S-A et al (2013) Survival outcomes of breast cancer patients who receive neoadjuvant chemotherapy: Associations with dynamic contrast-enhanced MR imaging with computer-aided evaluation. Radiology 268:662–672
17. Pickles MD, Lowry M, Manton DJ, Gibbs P, Turnbull LW (2005) Role of dynamic contrast enhanced MRI in monitoring early response of locally advanced breast cancer to neoadjuvant chemotherapy. Breast Cancer Res Treat 91:1–10
18. Hayes C, Padhani AR, Leach MO (2002) Assessing changes in tumour vascular function using dynamic contrast-enhanced magnetic resonance imaging. NMR Biomed 15:154–163
19. Chambers AF, Groom AC, MacDonald IC (2002) Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2:563–572